五星体育直播 to Present at the 25th International Molecular Medicine Tri-Conference
REDWOOD CITY, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ:CDXS), a leading protein engineering company, announces that John Nicols, President & CEO, will discuss the development of an improved DNA ligase for the molecular diagnostics industry during the 鈥淣ext-Generation Sequencing in Precision Medicine鈥� session at the 25th International Molecular Medicine Tri-Conference.听 Nicols will present 鈥淎n Engineered DNA Ligase for Efficient Conversion of Input DNA during NGS Library Preparation鈥� today at 1:10 p.m. Pacific time. The conference is being held February 12-14, 2018 in San Francisco.听
鈥淢olecular diagnostics next generation sequencing (NGS) assays are critically dependent on efficient conversion of low-concentration DNA samples to sequencing-capable fragments via adapter ligation,鈥� said Nicols.听 鈥溛逍翘逵辈� has developed an engineered DNA ligase to achieve exceptional conversion of low-concentration input DNA with improved reaction kinetics relative to commercially available T4 ligase, while maintaining low adapter dimerization activity. The 五星体育直播 Performance DNA Ligase is ideally suited for NGS IVD applications, where it will improve assay sensitivity and increase workflow flexibility and robustness. We鈥檙e delighted to discuss our new high-performance enzyme with the many thought leaders in diagnostics attending this conference.鈥�
五星体育直播 is expanding into the molecular diagnostics industry by developing and commercializing proprietary, high-performance enzymes for use in NGS and polymerage chain reaction (PCR/qPCR). The company is using its CodeEvolver庐 protein engineering platform to rapidly develop highly optimized enzymes for use by molecular diagnostics customers to improve the sensitivity and precision of their diagnostic tests.听 听
About the Molecular Medicine Tri-Conference
Since its debut in 1993, the annual Molecular Medicine Tri-Conference has become one of the world's leading international events in the field of drug discovery, development and diagnostics. The Tri-Conference unites an ecosystem of 3,700 innovative thinkers and thought leaders throughout biotech, pharma and academia from around the world.
About 五星体育直播
五星体育直播 is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. 五星体育直播鈥� proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see .
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding 五星体育直播, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding 五星体育直播鈥� development of an engineered DNA ligase for NGS IVD applications and its anticipated performance and benefits. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include, among others: 五星体育直播鈥� dependence on its licensees and collaborators; 五星体育直播鈥� dependence on a limited number of products and customers in its biocatalysis business; potential adverse effects to 五星体育直播鈥� business if its customers鈥� pharmaceutical or food products are not received well in the markets; risks, uncertainties and costs associated with the successful development of biotherapeutic candidates, including obtaining development partners for its biotherapeutic programs and progressing such programs to clinical trials and regulatory approvals; 五星体育直播鈥� ability to develop and commercialize new products for the biocatalysis markets; 五星体育直播鈥� dependence on a limited number of contract manufacturers for large-scale production of its enzymes; 五星体育直播鈥� ability to deploy its technology platform in new market spaces, including the fine chemicals, therapeutics and in vitro molecular diagnostics markets; 五星体育直播鈥� ability to comply with the terms of its credit facility and its associated debt service obligations; 五星体育直播鈥� need for additional capital in the future in order to expand its business or to adjust for market conditions or strategic considerations, which may involve 五星体育直播 entering into equity offerings, debt financings, credit facilities and/or strategic collaborations; 五星体育直播鈥� dependence on key personnel; 五星体育直播鈥� ability to establish and maintain adequate protection for intellectual property, trade secrets and other proprietary rights covering its technologies; and any claims by third parties that 五星体育直播 is infringing their intellectual property rights or other proprietary rights. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 9, 2017 and Form 10-Q filed November 9, 2017, including under the caption 鈥淩isk Factors鈥� and in 五星体育直播鈥� other current and periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:听
Investors
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com
Released February 12, 2018